Summary
Eli Lilly and Company (LLY) reported a net loss of $110.8 million for the first quarter of 2017, a significant shift from the $440.1 million net income in the same period of the prior year. This loss was primarily driven by a substantial $857.6 million charge for acquired in-process research and development (IPR&D) related to the acquisition of CoLucid Pharmaceuticals, which is not tax-deductible and heavily impacted profitability. Despite the net loss, total revenue saw a healthy increase of 7% to $5.23 billion, supported by strong volume growth in key products like Trulicity and Taltz, as well as the inclusion of revenues from the Boehringer Ingelheim Vetmedica acquisition. Investors should note the ongoing patent challenges for key products like Alimta, which, coupled with upcoming patent expirations for other significant products such as Strattera, Cialis, and Effient, present considerable future revenue risks. The company also saw increased operating expenses, with a 5% rise in marketing, selling, and administrative expenses, partly due to investments in new pharmaceutical products. While the company reaffirms its full-year revenue guidance, the EPS outlook has been revised downwards due to the IPR&D charge and restructuring costs.
Financial Highlights
52 data points| Revenue | $5.23B |
| Cost of Revenue | $1.35B |
| Gross Profit | $3.88B |
| R&D Expenses | $1.26B |
| SG&A Expenses | $1.57B |
| Operating Expenses | $2.83B |
| Interest Expense | $46.60M |
| Net Income | -$110.80M |
| EPS (Basic) | $-0.10 |
| EPS (Diluted) | $-0.10 |
| Shares Outstanding (Basic) | 1.06B |
| Shares Outstanding (Diluted) | 1.06B |
Key Highlights
- 1Total revenue increased by 7% to $5.23 billion, driven by volume growth in Trulicity, Taltz, and the inclusion of the Boehringer Ingelheim Vetmedica acquisition.
- 2The company reported a net loss of $110.8 million for the quarter, a reversal from a net income of $440.1 million in Q1 2016, largely due to an $857.6 million IPR&D charge from the CoLucid acquisition.
- 3Operating expenses increased by 3%, with Marketing, Selling, and Administrative expenses up 5% due to investments in new products.
- 4Significant charges of $213.9 million were recognized for asset impairment, restructuring, and other special charges, primarily related to cost reduction and integration efforts.
- 5The company faces significant patent expirations for key drugs like Strattera, Cialis, and Effient in 2017, posing future revenue risks.
- 6Cash and cash equivalents decreased to $2.62 billion from $4.58 billion at the end of 2016, largely due to investing and financing activities, including acquisitions.
- 7Full-year 2017 revenue guidance remains between $21.8 billion and $22.3 billion, but EPS guidance was revised downwards due to restructuring costs and the CoLucid acquisition impact.